Orasis Pharmaceuticals
Herzliya, Israel· Est.
Orasis delivers a prescription eye‑drop solution for presbyopia, aiming to reshape vision possibilities with a non‑invasive drug.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Orasis delivers a prescription eye‑drop solution for presbyopia, aiming to reshape vision possibilities with a non‑invasive drug.
Ophthalmology
Technology Platform
Low‑dose pilocarpine HCL ophthalmic solution that induces reversible miosis to enhance depth of focus for presbyopia treatment.
Opportunities
A large, aging global population creates strong demand for non‑invasive presbyopia treatments; Qlosi’s prescription model can capture patients seeking alternatives to glasses or surgery.
Risk Factors
Regulatory and reimbursement hurdles, competition from other ocular‑drop candidates, and potential safety concerns with chronic pilocarpine use could limit adoption.
Competitive Landscape
Competes with reading glasses, multifocal lenses, surgical options, and emerging eye‑drop therapies; Qlosi differentiates through rapid, reversible pharmacologic action and prescription convenience.